Self-emulsifying formulations of DIM-related indoles
Inventors
Zeligs, Michael A. • Jacobs, Irwin C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.
Core Innovation
The disclosed composition comprises a DIM-related indole and a carrier containing caprylocaproyl polyoxyl-8 glyceride, lauroyl polyoxyl-32 glyceride, phosphatidylcholine or lysophosphatidylcholine, oleoyl polyoxyl-6 glyceride, and a poloxamer copolymer. The poloxamer possesses a hydrophobic block with a molecular mass greater than 50% of its total molecular mass and a hydrophilic block under 2,250 Daltons. Upon dispersion in water or contact with gastrointestinal fluids, the composition emulsifies to form a dispersion of oil-in-water globules.
The multi-component carrier keeps poorly soluble DIM dissolved, limits recrystallization, and improves dispersed globule size, loading, and oral bioavailability. Formulations demonstrate higher plasma exposure than crystalline DIM or microencapsulated BR-DIM, with Formulation G providing higher exposure than Formulation D due to more stable self-emulsification. Additionally, Formulation G maintains approximately 12 to 13 percent DIM retention across three months of controlled storage.
Claims Coverage
The relevant claims identify one independent claim comprising one main inventive feature directed to a self-emulsifying DIM-related indole composition.
Self-emulsifying DIM-related indole composition
The independent claim covers a composition comprising a DIM-related indole and a carrier containing caprylocaproyl polyoxyl-8 glyceride, lauroyl polyoxyl-32 glyceride, phosphatidylcholine or lysophosphatidylcholine, oleoyl polyoxyl-6 glyceride, and a poloxamer copolymer. The poloxamer has a hydrophobic block with a molecular mass greater than 50% of its total molecular mass and a hydrophilic block with a molecular mass less than 2,250 Daltons. Upon dispersion in water or contact with gastrointestinal fluids, the composition emulsifies to form oil-in-water globules.
The independent claim covers the specified DIM-related indole carrier composition, its poloxamer block molecular-mass parameters, and its emulsification into oil-in-water globules in water or gastrointestinal fluids.
Stated Advantages
Phosphatidylcholine and poloxamer reduce dispersed globule size and inhibit recrystallization while keeping poorly soluble DIM dissolved.
The formulation improves solubilization in simulated intestinal digestion and enhances DIM loading, absorption, and oral bioavailability.
Human testing reports higher DIM plasma exposure with SMEDDS formulations than with crystalline DIM, spray-dried DIM, or microencapsulated BR-DIM, with Formulation D yielding a mean AUC of 1,507.2 ng/mL·h and Cmax of 363.2 ng/mL.
Formulation G shows greater AUC than Formulation D due to more stable self-emulsification and retains approximately 12–13% DIM during three months of controlled storage.
Documented Applications
Oral, rectal, or topical administration of the composition.
Treatment or prevention of acne, rosacea, atopic dermatitis, malaria, prostate cancer, psoriasis, or allergic contact dermatitis in a human subject.
Administration for acne or rosacea alone or in combination with retinyl palmitate.
Nutraceutical applications as identified in the description without further specific uses stated.
Interested in licensing this patent?